Three-Year Data of Zenflow's Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH
SOUTH SAN FRANCISCO, Calif., April 26, 2025 (GLOBE NEWSWIRE) — Zenflow, Inc. announced today the results of long-term data demonstrating that the investigational Zenflow Spring® System offers significant and durable benefits three years after placement. The Zenflow Spring is leading the way in establishing a new category of treatment, First-Line Interventional Therapy or 'FIT', for patients suffering from benign prostatic hyperplasia (BPH) or enlarged prostate. The goal of FIT is to provide clinicians with minimally invasive therapies that offer distinct safety advantages such as the ability to reverse treatment if desired, more like a medication. The research was presented at the 2025 Annual Meeting of the American Urological Association in Las Vegas.
Subjects treated with the Zenflow Spring showed statistically significant and sustained reduction in their International Prostate Symptom Score (IPSS) from baseline at all assessment time points. Highlights from the ZEST pilot studies include: At 36 months, IPSS was 46% improved relative to baseline (11.8 vs. 22.0).
The negative impact of BPH symptoms on quality of life was half that at baseline (IPSS-QOL 2.23 vs. 4.49), and Qmax increased to 13.9 mL/s from 10.6 mL/s at baseline.
The responder rate, calculated as the proportion of subjects with ≥ 30% improvement in IPSS, was 74% at 36 months, similar to 75% at 12 months and 70% at 24 months.
No deterioration in erectile or ejaculatory function was seen over time through 36 months.
Dean Elterman, M.D., Associate Professor at the University of Toronto and an attending urologist at the University Health Network, in Toronto, and investigator in the ZEST studies presented the research. 'It's exciting to see the front-runner in the FIT category continue to deliver consistent, long-term results for men living with BPH. Zenflow is the first to demonstrate this level of durability, and the only device offering a range of lengths and diameters to provide a truly tailored therapy. This new data reinforces earlier findings on durability and chronic safety, particularly the absence of implant encrustation or migration – making Zenflow a standout innovation in the field, and one to watch,' he said.
'We're encouraged to see the three-year data build upon the strong efficacy and durability results we saw at two years, further underscoring the Zenflow Spring as a promising, much-needed alternative for BPH patients and urologists seeking FIT options. We look forward to sharing developments with the urology community as we move toward FDA approval and commercial launch,' said Shreya Mehta, CEO.
The ZEST pilot studies included 72 subjects who received the Zenflow Spring device. Symptom improvement was measured using IPSS and IPSS-QOL; functional improvement was measured by peak urinary flow rate (Qmax). Overall effectiveness measures were calculated using a mixed model repeated measures (MMRM) analysis, which incorporates within-patient correlations and missing data, and equally weighs results from each study. Sexual health was monitored using the Sexual Health Inventory for Men (SHIM) and the Male Sexual Health Questionnaire –Ejaculatory Domain (MSHQ-EjD).
The safety and effectiveness of the Zenflow Spring System is currently being evaluated through BREEZE™, a large, multi-center, prospective randomized study in the United States and Canada.
About Zenflow
Zenflow, Inc. is a medical device company dedicated to improving treatment for patients suffering from urinary obstruction caused by enlarged prostate. The innovative Spring® technology was designed with the patient experience in mind and relies on a small spring-like coil that gently props open the urethra, restoring its normal function while preserving the natural anatomy. The Zenflow Spring System is an investigational device and is not approved for commercial sale.
For more information, visit www.zenflow.com, and for the latest updates, follow Zenflow on LinkedIn.
MEDIA CONTACT:
Rebecca Novak Tibbitt
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Medical Device Non-Conformance and Corrective Action for Manufacturers Training Course: Learn ISO 13485 and 21 CFR 820 Standards on Non-conformance Management (ONLINE EVENT: July 18, 2025)
Enhance your understanding of medical device Quality Management Systems (QMS) with our regulatory course. , CAPA processes, and root cause analysis to boost compliance and performance. Part of our Regulatory Affairs Training series. Dublin, June 16, 2025 (GLOBE NEWSWIRE) -- The "Non-Conformance and Corrective Action for Medical Device Manufacturers Training Course" training has been added to offering. This course provides an introduction to these regulatory requirements as they relate to the identification and handling of non-conformances and how manufacturers may demonstrate compliance. The identification of non-conformances and ensuring that they are dealt with in a timely and appropriate manner is a key part of any medical device Quality Management System (QMS). Regulations for medical device quality management systems include particular requirements for non-conformance, correction, corrective and preventative actions. These requirements relate to non-conformances identified through internal audits, external audits, routine processes, customer complaints vigilance and many other activities. Evidence of a QMS which deals with non-conformance and prevents recurrence is important and expected when demonstrating conformity with the regulations. These requirements are defined in ISO 13485, the international standard for medical device quality management systems, as well as in 21 CFR 820 and other global regulations. Benefits of Attending Understand the sources of non-conformance within a medical device QMS Learn techniques to establish the root cause of a non-conformance Understand the difference between containment, correction, corrective action, and preventative action Gain an awareness of the ways in which an effective Corrective and Preventative Action (CAPA) system can lead to improved performance and regulatory compliance Who Should Attend: Managers and supervisors working within a regulated Quality Management System (QMS) Regulatory Compliance specialists Quality Management System (QMS) specialists Internal Auditors Regulatory and Quality professionals Certification: CPD: 3 hours for your records Certificate of completion Key Topics Covered: Non-Conformance and Corrective Action Regulatory requirements for non-conformance and corrective action Definitions and understanding CAPA Sources of non-conformance and writing an effective statement of non-compliance The non-conformance and corrective action cycle Assessment of the risk associated with non-compliance Root cause analysis tools and methodology Correction, containment and impact assessment Taking effective corrective action to address root causes Evaluation of the effectiveness of corrective action Use of electronic quality management systems for non-conformance management Preventive Action Regulatory requirements for identification of preventive action Sources of preventive action and how to capture the details Root cause analysis Evaluation of the effectiveness of preventive action For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Root Cause Analysis (RCA) and Critical Thinking Training Course: Effective Tools and Techniques to Identify and Resolve Core Issues (ONLINE EVENT: July 15, 2025)
Enhance problem-solving skills in the pharmaceutical industry with our one-day Root Cause Analysis (RCA) and critical thinking course. Discover, optimize decision-making, and manage regulatory inspections. Gain CPD hours and certification. Dublin, June 16, 2025 (GLOBE NEWSWIRE) -- The "Root Cause Analysis and Critical Thinking Training Course" training has been added to offering. This one-day course introduces delegates to different RCA and critical thinking problem-solving tools and techniques which are then applied throughout a series of highly interactive and practical exercises putting these theories into practice to apply a systematic end-to-end process for analysing problems and decision making. Root Cause Analysis (RCA) is the process of discovering the root causes of problems to identify solutions. When used with critical thinking, the ability to think clearly and rationally, understanding the logical connection between ideas this provides a highly effective method for identifying the source of faults, failures, decision-making, and undesired outcomes for processes. This approach is extremely effective when used by the pharmaceutical and associated healthcare industries to solve problems. In addition, RCA procedures with the application of critical thinking are an increasing focus by regulatory inspectors. Often organisations waste a great amount of time and money in fixing the symptoms of a problem, rather than the problem itself. Using Critical thinking applied to RCA will enable you to solve problems far quicker, and much more effectively. This training course is part of a collection of trainings which focus on leadership, innovation, strategy, communication, finance, problem solving and conflict management, to name a few key areas. Benefits of attending Apply best practice tools and techniques to identify, and document the root causes of problems Propose and evaluate solutions to prevent problems recurring and manage regulatory inspection findings Communicate your findings and recommendations to colleagues and senior management Gain an overview of the increasing importance of RCA and critical thinking skills for pharmaceutical and biopharmaceutical and associated healthcare sectors Understand the critical thinking and application to RCA Be aware of key tools and approaches to apply critical thinking to RCA for pharmaceutical and associated healthcare industries Who Should Attend: Anyone working in the pharmaceutical, biopharma, medical device and veterinary industries who wants to maximise RCA and critical thinking skills, particularly applied to problem solving and decision making including the following: Managers responsible for process and quality improvements Professionals working in R&D and production Quality managers, internal and external auditors, inspectors Line managers and supervisors Anyone involved in managing customer and/or supplier/CMOs, CRO relationships Problem solving team members and leaders Product or process designers Operational and production professionals Certifications: CPD: 6 hours for your records Certificate of completion Key Topics Covered: Background and defining RCA and critical thinking Steps in RCA and applying critical thinking Preventive/Mitigating problems Preventive action Risk analysis Failure Mode and Effects Analysis (FMEA) Diagnosing RCA RCA Methodologies Brainstorming Ishikawa Diagrams Five "Why?"s Is/is not Process maps Critical Thinking Overview of background Define critical thinking, decision making and problem-solving and understand the differences Examine types of decisions & problems in the pharma industry Understand the focus of critical thinking in ICH Designing Quality Applying critical thinking to thinking questions to go beyond checklists Tools and approaches for critical thinking to use in the pharmaceutical and associated healthcare industries including RED thinking outside the box ways to improve your critical thinking Speakers: Laura Brown Pharmaceutical QA and Training Consultant University of Cardiff Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. She has more than 20 years' experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International. She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry. She regularly writes on pharmaceutical regulatory issues including "The Planning of International Drug Development", in the Clinical Research Manual, Euromed and the "Impact of Brexit", RQA Journal 2017. For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Business Wire
an hour ago
- Business Wire
D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced positive results from DD01-DN-02 study, an ongoing 48-week Phase 2 trial designed to evaluate the efficacy and safety of DD01 (a once-weekly dual GLP1/glucagon receptor agonist) in 67 overweight/obese subjects with MASH. DD01 treatment was initiated with two weeks of dosing at 20 mg, followed by the 40mg once-weekly maintenance dose. Results of a planned 12-week assessment of safety and efficacy revealed DD01 was well tolerated, and the study's primary endpoint was met. Following a 1:1 randomization of 40mg DD01 and placebo, 75.8% of subjects treated with DD01 achieved at least a 30% reduction in liver fat, 72.7% of subjects achieved greater than 50% reduction in liver fat, and 57.6% of subjects achieved greater than 70% liver fat reduction (in each case, with p < 0.0001). DD01 achieved a mean reduction of liver fat content of 62.3% vs 8.3% for placebo at 12 weeks of treatment, and 48.5% of DD01 subjects achieved normalization of liver fat fraction (defined as liver fat fraction of 5% or less by MRI-PDFF). No placebo subject achieved normalization. Treatment related reductions in Non-invasive markers of MASH progression were used to evaluate subjects at baseline and after 12 weeks of treatment. DD01 treatment was associated with statistically significant improvements in liver stiffness (MRE), pro-C3 levels, and ELF score. Additional Endpoints Twelve-week weight loss data were encouraging. While placebo-treated subjects had no significant weight loss, 42.4% of DD01-treated subjects achieving a greater than 5% reduction in weight. Also encouraging were the results of HbA1c testing. While the study population was not selected to be diabetic, following 12 weeks of DD01 treatment, HbA1c reduction was statistically significant compared to placebo. Safety Results DD01 was well tolerated. Gastrointestinal (GI) side effects were most common, generally mild to moderate, but transient and manageable. To date, only 3 subjects have discontinued treatment due to GI-related adverse events. Implications Seulki Lee, Ph.D., President and Chief Executive Officer of D&D Pharmatech, stated, 'We have remarkably positive results for DD01 after only 12 weeks of treatment in MASH. The magnitude of improvements is equivalent to what has been achieved only after longer-term treatment with FGF and GLP-1 based drugs already validated with histology data in MASH.' 'Considering the combination of liver and metabolic benefits and the favorable tolerability profile, DD01 has the potential to provide patients and physicians with a MASH treatment that is easy to manage, encourages weight loss and is diabetes friendly.' Mazen Noureddin, MD, MHSc, Professor of Medicine at Houston Methodist Hospital; Co-Chairman of the Board, Summit & Pinnacle Clinical Research; Director, Houston Research Institutes, commented, 'The degree of liver fat reduction with DD01 is striking, with nearly three-quarters of patients achieving at least a 30% reduction and almost half reaching normalization within just 12 weeks. The observed improvement in liver stiffness by MRE, though early, adds further support to the biological activity of this dual GLP-1/glucagon approach, which is designed to act directly on the liver.' 'These consistent MRI-PDFF results provide strong confidence that DD01 has the potential to meet both key regulatory endpoints - MASH resolution and fibrosis improvement - as the program advances. Coupled with favorable metabolic effects and a very low treatment discontinuation rate, DD01 is emerging as a well-differentiated and promising therapy, both within its class and compared to other potent agents in development.' Additional data will be presented at upcoming medical meetings. About DD01 DD01 is a once-weekly dual GLP1/glucagon receptor agonist with a half-life of 7-8 days in obese/overweight patients with T2D and MASLD. Following a Phase 1 study that showed DD01 rapidly reduced liver steatosis, improved glucose tolerance, and encouraged weight loss in obese subjects with MASLD and type 2 diabetes, FDA granted DD01 Fast Track Designation for the treatment of MASH. Current Phase 2 results confirm and extend these findings revealing additional benefits in patients with MASH. The effect of DD01 is consistent with its dual-agonist pharmacology. Clinical results show the effects of DD01 are remarkably rapid. DD01 achieves robust results rapidly and with tolerability comparable to other validated MASH treatments. The GLP1:glucagon potency ratio for DD01 is 11:1. GLP-1R potency is likely an important driver in glucose management for diabetic patients and in weight loss. Importantly, with this ratio, DD01 is clearly also a potent glucagon receptor agonist. Substantial liver fat reduction was observed after only 4 weeks in obese subjects with MASLD (Phase 1). Liver fat reduction by DD01 is clearly not secondary to weight loss at these early timepoints, differentiating it mechanistically from the pure incretin approach. In terms of the balance between efficacy and tolerability, the pharmacokinetics of DD01 are also unique. Good tolerability at clinically active doses is likely aided by very slow absorption (tmax = 6 days) and a long half-life (7-8 days), features which make the onset and rise in DD01 exposure gradual. Peaks associated with poor tolerability and troughs associated with diminished efficacy are avoided. As a result, the need for a lengthy titration period is eliminated and therapeutic levels are reached rapidly. A key differentiator for DD01 is the balanced constellation of clinical benefits afforded by a unique pharmacologic and pharmacodynamic signature. Current data suggest DD01 has the necessary attributes to offer patients and physicians a treatment that is easy to use, supports both liver and metabolic health. About the DD01-DN-02 Trial With the support of staff at Summit Clinical Research, the study investigators, and the study participants, the DD01-DN-02 study is fully enrolled and currently ongoing at 12 centers in the U.S. Baseline characteristics were well balanced between both treatment groups with nearly identical mean liver fat fractions (overall mean of 20.7%) and similar body weight (overall mean 99.4 kg) at baseline. Treatment is ongoing and the study includes non-invasive and histologic assessments of MASH resolution and change in fibrosis at 48 weeks. More information about the study is available at under the identifier NCT06410924. About D&D Pharmatech D&D Pharmatech is a clinical-stage biopharmaceutical company focused on developing revolutionary medicines for patients with a number of metabolic, fibrotic, and neurodegenerative diseases. DD01 and TLY012 are in development for fibrotic liver disease (MASH and cirrhosis). TLY012 has completed IND-enabling studies and has been shown to slow and even reverse established fibrosis in models of liver cirrhosis, chronic pancreatitis, and systemic scleroderma. Two products are in development for neurodegenerative diseases. NLY02 is a small molecule BBB penetrating kinase inhibitor targeting glial activation. It is a potent inhibitor of neurodegeneration. NLY01 is also a potent inhibitor of glial activation. It acts through the incretin pathway to reduce neuronal loss and slow functional decline in models of Parkinson's, Alzheimer's, and multiple sclerosis. In a recently completed Phase 2 study conducted in >250 Parkinson's patients, 36-week of treatment with NLY01 resulted in a significant reduction in motor function decline (UPDRS III) in ~1/3 of trial subjects. NLY01 appeared to slow the progressive decline in motor function in newly diagnosed patients who were young (<60) and treatment naïve. D&D Pharmatech's ORALINK technology allows efficient oral uptake of therapeutic peptides. In partnership with Metsera, the company is developing orally active incretin-based peptide drugs for obesity.
